Cantor Fitzgerald reiterates Overweight on BridgeBio Pharma stock

Cantor Fitzgerald has renewed its Overweight rating on BridgeBio Pharma (NASDAQ:BBIO) with a price target of $110.00, reflecting the firm's belief in the stock's potential despite recent challenges. Shares have slipped to the mid-$60 range following a peak above $90 in July, currently sitting at $67.25. This represents a 28% decline from its 52-week high of $93.42, with year-to-date performance dropping 12%.

The firm identified several factors contributing to the stock's weakness, including competitive pressures and uncertainty surrounding BridgeBio's quarterly results. However, the investment bank pointed out that several analysts have lowered their earnings forecasts for the upcoming period, indicating growing caution among market participants.

One specific concern highlighted by Cantor Fitzgerald is the slowing growth attributed to Attruby, the company's flagship product. The firm noted that growth was expected to decelerate through year-end, reaching approximately $25 million to $30 million per quarter, before potentially accelerating afterward.

Despite these challenges, BridgeBio Pharma recently reported strong second-quarter 2026 revenue of $243.7 million, exceeding analyst estimates of $221 million. The company's U.S. net product revenue from Attruby contributed significantly to this figure, driven by treatment-naïve first-line starts.

Recent analyst upgrades have also bolstered confidence in BridgeBio Pharma. Canaccord raised its price target to $106 from $104, maintaining a Buy rating, while Mizuho increased its target to $110 from $96, assigning an Outperform rating. This optimism was further reinforced by H.C. Wainwright, which maintained its Buy rating with a higher price target of $120 following promising data from BridgeBio's ATTRibute-CM study.

The study, presented at the European Society of Cardiology Congress 2026, showcased important cardiac magnetic resonance imaging results and an open-label extension.

Additionally, H.C. Wainwright highlighted new exploratory analyses from the PROPEL 3 study, examining the oral infigratinib in children with achondroplasia. This positive sentiment was echoed by KKR Genetic Disorder L.P., which announced a secondary public offering to sell 5 million shares of BridgeBio common stock, though the company would not be selling any shares or receiving proceeds from this transaction.